Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

Citations Over TimeTop 10% of 2017 papers

Abstract

The indisputable role of epigenetics in cancer and the fact that epigenetic alterations can be reversed have favoured development of epigenetic drugs. In this study, we design and synthesize potent novel, selective and reversible chemical probes that simultaneously inhibit the G9a and DNMTs methyltransferase activity. In vitro treatment of haematological neoplasia (acute myeloid leukaemia-AML, acute lymphoblastic leukaemia-ALL and diffuse large B-cell lymphoma-DLBCL) with the lead compound CM-272, inhibits cell proliferation and promotes apoptosis, inducing interferon-stimulated genes and immunogenic cell death. CM-272 significantly prolongs survival of AML, ALL and DLBCL xenogeneic models. Our results represent the discovery of first-in-class dual inhibitors of G9a/DNMTs and establish this chemical series as a promising therapeutic tool for unmet needs in haematological tumours.

Related Papers

• → Unusual Sites of Arginine Methylation in Poly(A)-binding Protein II and in Vitro Methylation by Protein Arginine Methyltransferases PRMT1 and PRMT3(1999)143 cited
• → Methylation of phytohormones by the SABATH methyltransferases(2010)17 cited
• → An Abnormal Methylation Ratio Induces Hypomethylation In Vitro in the Brain of Pig and Man, But Not in Rat(1995)32 cited
• Methylation of phytohormones by the SABATH methyltransferases(2010)
• → Structural Insights of Outer Membrane Protein Methyltransferases from Rickettsia(2013)